MDS: Plerixafor in combination with G-CSF/azacitidine shows promise in phase 1February 1, 2021Myelodysplastic Syndrome
Lenalidomide-epoetin alfa vs. lenalidomide alone in MDS refractory to recombinant erythropoietinFebruary 1, 2021Myelodysplastic Syndrome
Higher-risk MDS: Azacitidine plus pembrolizumab shows promiseFebruary 1, 2021Myelodysplastic Syndrome
Flow cytometry identifies rare combination of lymphoma and MDSJanuary 5, 2021Myelodysplastic Syndrome
Poor outcomes persist for MDS, ALL, AML patients who relapse after cell transplantsJanuary 5, 2021Myelodysplastic Syndrome
Revised scoring system enhances prognostic value for MDS patients treated with 5-AZAJanuary 5, 2021Myelodysplastic Syndrome
MDS patients who responded to azacytidine showed low levels of Wilms’ tumor 1January 5, 2021Myelodysplastic Syndrome
A modified flow cytometry score effectively evaluates risk in myelodysplastic syndromeJanuary 5, 2021Myelodysplastic Syndrome
Older adults with myelodysplastic syndrome can benefit from transplantsJanuary 5, 2021Myelodysplastic Syndrome
